Comparative Efficacy of Treatment Options for Minimal Hepatic Encephalopathy: A Systematic Review & Network Meta-analysis.

Clicks: 257
ID: 31593
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #21 of 38 articles by views in clinical gastroenterology and hepatology : the official clinical practice journal of the american gastroenterological association

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
To synthesize evidence for most effective treatment for minimal hepatic encephalopathy (HE).A systematic search of the PubMed, EMBASE, OvidSP and CENTRAL databases for randomized-controlled-trials evaluating treatments for minimal HE in cirrhotics was conducted from their inception to 26July2018. Primary outcomes were reversal of minimal HE and prevention of overt HE. Meta-analysis (MA) followed by network meta-analysis (NMA) and surface under cumulated ranking (SUCRA) was conducted to pool the direct and indirect estimates and rank the different treatments. Quality appraisal was done using GRADE.Twenty-five trials (1563 participants) were inlcuded in MA and NMA. Rifaximin [OR:7.53; 95%predictive interval(PrI): 4.45-12.73, SUCRA:89.2%; moderate quality], lactulose [OR:5.39; 95% PrI:3.60-8.07, SUCRA:67.2%; moderate quality], probiotics+lactulose [OR:4.66; 95% PrI:1.90-11.39, SUCRA:52.4%; low quality], L-ornithine L-aspartate [OR:4.45; 95% PrI:2.67-7.42, SUCRA:47.2%; moderate quality] and probiotics [OR: 3.89; 95% PrI: 2.52-6.02, SUCRA:34.1%; low quality] were effective in reversing minimal HE as compared with placebo/no-treatment. L-Ornithie L-Aspartate [OR:0.19; 95% PrI:0.04-0.91, SUCRA:75.1%; moderate quality], lactulose [OR:0.22; 95% PrI:0.09-0.52, SUCRA73.9%; moderate quality] and probiotics [OR: 0.27; 95% PrI:0.11-0.62, SUCRA:59.6%; low quality] were effective in preventing episodes of overt HE, as compared with placebo/no-treatment. On comparative analysis, no superiority was identified between agents, except rifaximin over probiotics (very low quality) for reversal of minimal HE.Rifaximin and lactulose were most effective for reversal of minimal HE. L-Ornithine L-Aspartate and lactulose were most effective in prevention of overt HE. Lactulose was the only agent effective in reversing minimal HE, preventing overt HE, reducing ammonia and improving quality of life; but with tolerable adverse effects. (PROSPERO-ID:107003).
Reference Key
dhiman2019comparativeclinical Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Dhiman, Radha K;Thumburu, Kiran K;Verma, Nipun;Chopra, Madhu;Rathi, Sahaj;Dutta, Usha;Singal, Ashwani K;Taneja, Sunil;Duseja, Ajay;Singh, Meenu;, ;
Journal clinical gastroenterology and hepatology : the official clinical practice journal of the american gastroenterological association
Year 2019
DOI
S1542-3565(19)30969-3
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.